Together with Sideways Frequency*

BioStem Technologies (BSEM) is making waves with insane revenue growth, groundbreaking tech in regenerative medicine, and some big moves on the horizon like a potential Nasdaq uplist. This stock has been on fire, and today could get even more interesting. Check it out and see what you think!

TODAY’S TOP ALERT! 

OTC: BSEM

⏰ Set a reminder to join me LIVE @ 11am EST today as I review my top trading ideas for the week in the Market Master’s trading room

Good morning, Folks,

Now-President Donald Trump is promising us that "The golden age of America begins right now” and that “America’s decline is over.”

No matter what side of the political fence you are on, for America’s sake… let’s hope he’s right!

He signed a flurry of executive orders yesterday and promises to unleash American energy and industry. 

One of my favorite investors, Stanley Druckenmiller, said on CNBC yesterday that, “We’re going from the most anti-business administration to the opposite.”

Tech titans seem especially enthused, and as we know, their companies are the real market-makers of the day.

I love trading regardless of the market environment, but it always feels easier when there’s widespread optimism, like now. 

I think today is the perfect time to revisit one of the hottest stocks in the market…

The stock is up an incredible 1,500% in the last three years, including a 150%+ gain over the past year.

It’s very rare that I point to an OTC idea, but this is one of the very few OTC stocks worth looking at.

Without further ado, go ahead and pull up BioStem Technologies, Inc. (BSEM) on your favorite trading platform.

Check out this beauty!

Some important levels I want to point out above would be around $12, which has been tested multiple times over the last few months as lower support.  If that price falls, I would be very cautious and expect a downtrend to follow.

On the upside, BSEM is very close to the upper-limit resistance around $18, which was rejected in December.

Before that, you can see that BSEM made a major breakout past that level and soared all the way to $28, which was a 130%+ move in a few weeks’ time.

Keep a very close eye on that upper level now, and see if BSEM can surge past it once again.

If you recall, the stock had a 16% rally in a single day the last time I alerted it in November, and I’ve been following its encouraging price action ever since.

Thanks to a wave of great news, the wind is clearly at its back…

From its recent low on December 30, the stock has rallied 35% and the barchart indicators are screaming “BUY” for the medium and long term:

Not to mention the “STRONG BUY” consensus from TipRanks for the one-hour analysis:

Stock futures are looking great, and I think today could be especially explosive 💥 for BSEM.

This is my 👉#1 ALERT👈  for the day so be sure to keep it at the very top of your radar!

Once you look into the company, I think you’ll be very impressed.

Not to bury the lede, the company has posted astonishing gains on its financials lately. Some highlights from its press release last Monday:

• “Fourth quarter net revenue is expected to be approximately $102.9 million,” marking a nearly 800% increase from the prior year.

• “Full-year 2024 net revenue is expected to be approximately $301.8 million,” a more than 1,700% increase!

• “Fourth quarter gross profit is expected to be approximately $99.3 million, compared to $10.9 million for the fourth quarter of 2023.” Another 800% increase.

• And “Full-year 2024 gross profit is expected to be approximately $288.1 million, compared to $15.4 million for fiscal year 2023.” Another 1,700+% increase. 

With financials like these, the stock’s triple-digit growth over the past year becomes perfectly understandable.

This wasn’t based on “hopes and dreams” but on a fat and growing bottom line.

👉 But here’s the thing:  Zacks Small Cap Research has initiated coverage on BSEM and right now has a $32.50 12-month price target for it.

That’s a 104% upside from its closing price on Friday, and certainly doesn’t seem unreasonable based on the company’s explosive growth.

So what exactly is BSEM up to?

The company is a Florida-based commercial-stage company focused on development, manufacture, and commercialization of placental-derived allografts for advanced wound care.

It says it wants to be the “global leader in regenerative medicine.”

It currently has four placental-derived allograft products on the market. An allograft is “tissue recovered from a human donor for transplantation into another person.”

For more than 100 years, doctors have used the human amniotic membrane to help heal wounds. The membranes are rich in “growth factors, extracellular matrix (ECM) components, and cytokines which are known to support the body’s natural healing processes.”

Furthermore, they are seemingly immune-neutral and “disappear and integrate with the patient’s own tissue without a host reaction.”

BSEM’s innovation is its patented BioREtain process which “preserves the integrity of the amniotic tissue factors critical to the healing process.”

The resulting allografts are sterile, can be stored at ambient temperature, and are shelf-stable up to four years.

As of September, the company had recovered 5,000+ placentas and distributed more than 100,000+ allografts.

Retrospective studies — including this one published in the peer-reviewed International Wound Journal in October — have found that BSEM’s allografts:

• Promote faster wound healing times

• Require fewer applications

• Can reduce healthcare costs

• Improve patient outcomes

The company launched a clinical trial in October to evaluate one of its allograft products “against the standard of care for patients suffering from non-healing diabetic foot ulcers (DFUs).”

Two weeks ago, it launched another, similar trial for another one of its allograft products.

DFUs are surprisingly common, with 15% of diabetics developing them at some point, and between 14% and 24% of those who get them will ultimately need an amputation (!).

In October, BSEM announced that its second product qualified for “nationwide Medicare reimbursement” and would be available in all 50 states.

Then on November 20, the company signed a letter of intent to acquire the medical device company ProgenaCare. You can read about the company’s products at the link, but BSEM CEO Jason Matuszewski says they “align perfectly with our goal to provide wound-care solutions across the entire continuum of care.”

The company said it “expects to finalize definitive agreements within 60 days following customary due diligence.” By my math, that’s right about now, so this could be a huge, imminent catalyst.

Another really big potential catalyst is the company’s September 30 application to uplist to the Nasdaq, a process which it expected as of August could be complete in 60-90 days.

Again, by my math, that could happen any day now, and I’m sure I don’t have to tell you what a huge boost it can be for a stock’s visibility and credibility to uplist from OTC to the Nasdaq.

But even trading OTC, the company has managed to climb from penny-stock status to a $15.90 stock price with a $259 million market cap. That’s truly impressive, and if the Nasdaq uplist goes through, that should be a huge shot in the arm.

I strongly recommend doing your own homework on BSEM ASAP. With exploding revenues and a number of big potential catalysts coming down the line, this one could make a powerful move, imminently.

This investor presentation is a great place to start as is the company website and this Zacks report from May.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: BSEM is one of the best performing stocks out there. The company has an estimated revenue pipeline at $301.8 million for 2024, including a gross profit of $288.1 million.

And with talk of a business acquisition and potential uplisting to the Nasdaq, it is absolutely one of the best opportunities to look into right now.

Pay close attention to BSEM today as we see if its incredible rally will power on.

To Your Success,

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty one thousand five hundred dollars (cash) from Sideways Frequency for advertising BioStem Technologies, Inc for a one day marketing program on January 21, 2025. Before this, we received ten thousand dollars (cash) from Sideways Frequency for advertising BioStem Technologies, Inc for a one day marketing program on November 18, 2024. This was paid by someone else not connected to BioStem Technologies, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into BioStem Technologies, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.